Literature for LBQ657 (M13.001 inhibitor)

(Topics flags: S Structure, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2020
1. Salazar,J., Rojas-Quintero,J., Cano,C., Perez,J.L., Ramirez,P., Carrasquero,R., Torres,W., Espinoza,C., Chacin-Gonzalez,M. and Bermudez,V.
   Neprilysin: a potential therapeutic target of arterial hypertension?
   Curr Cardiol Rev16, 25-35. PubMed  Europe PubMed DOI  I
2. Teyssier,V.R., Simard,J.M., Dornan,M.H., Tournoux,F. and DaSilva,J.N.
   Radiosynthesis of the (11) C-methyl derivative of LBQ657 for PET investigation of the neprilysin inhibitor sacubitril
   J Labelled Comp Radiopharm63, 65-71. PubMed  Europe PubMed DOI  I
2019
3. Esser,N. and Zraika,S.
   Neprilysin inhibition: a new therapeutic option for type 2 diabetes?
   Diabetologia62, 1113-1122. PubMed  Europe PubMed DOI  I
2018
4. Campbell,D.J.
   Neprilysin inhibitors and bradykinin
   Front Med (Lausanne)5, 257-257. PubMed  Europe PubMed DOI  I
2017
5. Bartell,N. and Frishman,W.H.
   Neprilysin inhibition and the treatment of heart failure: recent steps in the right direction
   Cardiol Rev25, 315-320. PubMed  Europe PubMed DOI  I
6. Owens,A.T., Brozena,S. and Jessup,M.
   Neprilysin inhibitors: emerging therapy for heart failure
   Annu Rev Med68, 41-49. PubMed  Europe PubMed DOI  I
7. Salazar Adum,J.P. and Arora,R.
   Role of neprilysin inhibitors in heart failure
   Am J Ther24, e737-e737. PubMed  Europe PubMed DOI  I
2016
8. Bayes-Genis,A., Morant-Talamante,N. and Lupon,J.
   Neprilysin and natriuretic peptide regulation in heart failure
   Curr Heart Fail Rep13, 151-157. PubMed  Europe PubMed DOI  I
9. Feldman,A.M.
   Neprilysin inhibition in the time of precision medicine
   JACC Heart FailS2213-1779, 30049-X-30049-X. PubMed  Europe PubMed DOI  I
10. Howell,E.H. and Cameron,S.J.
    Neprilysin inhibition: a brief review of past pharmacological strategies for heart failure treatment and future directions
    Cardiol J23, 591-598. PubMed  Europe PubMed DOI  I
11. Hsiao,R. and Greenberg,B.
    Neprilysin Inhibition as a PARADIGM Shift in heart failure therapy
    Curr Heart Fail Rep13, 172-180. PubMed  Europe PubMed DOI  I
12. Schiering,N., D'arcy,A., Villard,F., Ramage,P., Logel,C., Cumin,F., Ksander,G.M., Wiesmann,C., Karki,R.G. and Mogi,M.
    Structure of neprilysin in complex with the active metabolite of sacubitril
    Sci Rep6, 27909-27909. PubMed  Europe PubMed DOI  S  I
2015
13. Judge,P., Haynes,R., Landray,M.J. and Baigent,C.
    Neprilysin inhibition in chronic kidney disease
    Nephrol Dial Transplant30, 738-743. PubMed  Europe PubMed DOI  I
14. McMurray,J.J.
    Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances
    Eur J Heart Fail17, 242-247. PubMed  Europe PubMed DOI  I
15. Vodovar,N., Paquet,C., Mebazaa,A., Launay,J.M., Hugon,J. and Cohen-Solal,A.
    Neprilysin, cardiovascular, and Alzheimer's diseases: the therapeutic split?
    Eur Heart J36, 902-905. PubMed  Europe PubMed DOI  I
2014
16. Jessup,M.
    Neprilysin inhibition - a novel therapy for heart failure
    N Engl J Med371, 1062-1064. PubMed  Europe PubMed DOI  I